PTC Therapeutics' ataluren fails late-stage study in patients with nonsense mutation cystic fibrosis
Since we got the sad news that Ataluren failed in the late stage study...we have some good news:
Indrepta, a nutritional supplement for non sense mutations, is now on the market!
Jim Caldwell and the Sharktank group are doing amazing work getting new supplements to our community.
Jim has helped us in many ways here at the forums with his expertise in IT too. We are grateful!
Salt and Light,
Jeanne
Since we got the sad news that Ataluren failed in the late stage study...we have some good news:
Indrepta, a nutritional supplement for non sense mutations, is now on the market!
Jim Caldwell and the Sharktank group are doing amazing work getting new supplements to our community.
Jim has helped us in many ways here at the forums with his expertise in IT too. We are grateful!
Salt and Light,
Jeanne